Physician profile
Suzanne Pierce
NPI 1841957941
$2,764.63
in general payments reported to CMS, 2019-2025
34 companies · $930 in 2025
The $930 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $266 · 2023: $623 · 2024: $946 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,499.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $573.92 | 2022-2025 | |
| Lilly USA, LLC | $412.93 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $304.78 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $300.03 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Dexcom, INC. | $136.05 | 2023-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Merck Sharp & Dohme LLC | $107.77 | 2023-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| Teva Pharmaceuticals USA, INC. | $89.81 | 2023-2024 | Ajovy, Austedo Xr, Uzedy |
| Vertex Pharmaceuticals Incorporated | $80.80 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $78.34 | 2025 | Caplyta |
| Pfizer INC. | $64.82 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $59.89 | 2023-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $49.72 | 2023-2025 | Rexulti |
| Organon LLC | $47.05 | 2022-2023 | Nexplanon |
| Amgen INC. | $42.97 | 2023-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $42.87 | 2025 | Veozah |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $28.99 | 2024 | |
| Kyowa Kirin, INC. | $27.69 | 2025 | |
| Scynexis, INC. | $27.61 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.49 | 2022-2023 | |
| Lundbeck LLC | $24.01 | 2025 | Rexulti |
| Radius Health, INC. | $23.76 | 2025 | Tymlos |
| Neurelis, INC. | $22.29 | 2023 | Valtoco |
| Novartis Pharmaceuticals Corporation | $21.59 | 2025 | |
| Nevro Corp. | $21.53 | 2023 | Senza |
| Vanda Pharmaceuticals INC. | $17.33 | 2023 | Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $16.79 | 2023 | Trintellix |
| Exeltis, USA INC. | $15.71 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.60 | 2023 | Xifaxan |
| Endogastric Solutions, INC | $14.51 | 2023 | Esophyx |
| Exact Sciences Corporation | $14.23 | 2025 | Cologuard Collection Kit |
| Myovant Sciences INC. | $13.95 | 2022 | |
| Mylan Specialty L.P. | $13.85 | 2023 | Yupelri |
| Coopersurgical, INC. | $13.85 | 2022 | |
| Agile Therapeutics, INC. | $13.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.